Skip to main content

Madrigal Pharmaceuticals, Inc.

MDGL
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001157601

In the last 90 days, Madrigal Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 3 sales; 414 institutions reported holding it in 13F filings for Q2 2026, worth $12.7B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Madrigal Pharmaceuticals, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
3 filings
2 insiders, $7.95M in total
Insiders trading
2
Net value
−$7.95M
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Madrigal Pharmaceuticals, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Madrigal Pharmaceuticals, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Sibold William JohnPresident and CEO197,746Sep 11, 20265
Kelley Shannon TGeneral Counsel11,474Aug 20, 20263
Reed John CDirector647Aug 18, 20261
Baker JulianDirector1,948,876IndirectJun 18, 20261
Baker FelixDirector1,948,876IndirectJun 18, 20261
Baker Bros. Advisors LPDirector1,948,876IndirectJun 18, 20261
Baker Brothers Life Sciences LPDirector1,948,876IndirectJun 18, 20261
667, L.P.Director1,948,876IndirectJun 18, 20261
Baker Bros. Advisors (GP) LLCDirector1,948,876IndirectJun 18, 20261
Fouse Jacqualyn ADirector1,551Jun 18, 20261
Taub RebeccaDirector452,667Jun 18, 20267
Levy Richard SDirector22,469Jun 18, 20265
Daly James MDirector3,081Jun 18, 20261
Brennan Daniel J.Director1,371Jun 18, 20261
Soergel DavidChief Medical Officer10,033Jun 1, 20263
Dier MardiEVP and CFO12,490Mar 6, 20263
Huntsman CaroleChief Commercial Officer12,692Mar 6, 20263
Thakkar RitaChief Accounting Officer2,398Jan 20, 20261
Friedman Paul ADirector187,164Jan 13, 20263
Bate KennethDirector2,627Nov 7, 20251
Craves Fred BDirector350,076Mar 14, 20250
Waltermire Robert E.Senior VP, Chief Pharma Dev.5,789Mar 7, 20250
Lynch Brian JosephSVP and General Counsel17,691Jan 25, 20240
Howarth Alex G.Chief Financial Officer18,737Jan 25, 20240
Sukhija RemyChief Commercial Officer15,001Jan 18, 20230
Milligan David VDirector–Jun 21, 20220
Gollust Keith RDirector–Jun 21, 20220
Bay City Capital LLC10% Owner1,261Dec 7, 20210
Bay City Capital Fund IV Co Invesment Fund LP10% Owner1,261Dec 7, 20210
Bay City Capital Management IV LLC10% Owner1,261Dec 7, 20210
Bay City Capital Fund IV, L.P.10% Owner1,261Dec 7, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 11, 2026 (view filing)4:57 PM ETSep 9-112 daysSibold William JohnPresident and CEOSSale−11.6K$538.65−$6.24M−5.5%197.7K after24 lots10b5-1
Aug 20, 2026 (view filing)4:20 PM ETAug 173 daysLateKelley Shannon TGeneral CounselSSale−664$514.97−$341.9K−5.5%11.5K after
Jul 20, 2026 (view filing)9:16 PM ETJul 20Same daySibold William JohnPresident and CEOSSale−2.50K$547.30−$1.37M−1.2%209.3K after10 lots
Jun 1, 2026 (view filing)Jun 1Same daySoergel DavidChief Medical OfficerSSale−1.04K$495.74−$516.6K−9.4%10.0K after10b5-1
May 22, 2026 (view filing)May 22Same dayLevy Richard SDirectorSSale−5.68K$515.44−$2.93M−20.5%22.0K after12 lots10b5-1
May 18, 2026 (view filing)May 18Same daySoergel DavidChief Medical OfficerSSale−844$515.90−$435.4K−7.1%11.1K after
Mar 6, 2026 (view filing)Mar 6Same dayDier MardiEVP and CFOSSale−1.98K$430.87−$854.0K−13.7%12.5K after12 lots10b5-1
Mar 6, 2026 (view filing)Mar 6Same daySibold William JohnPresident and CEOSSale−1.66K$431.94−$718.3K−1.0%161.8K after
Mar 6, 2026 (view filing)Mar 6Same dayKelley Shannon TGeneral CounselSSale−360$431.94−$155.5K−2.9%12.1K after
Mar 6, 2026 (view filing)Mar 6Same dayHuntsman CaroleChief Commercial OfficerSSale−419$431.94−$181.0K−3.2%12.7K after
Mar 6, 2026 (view filing)Mar 6Same dayTaub RebeccaDirectorSSale−491$431.94−$212.1K−0.1%452.2K after
Mar 2, 2026 (view filing)Mar 2Same dayDier MardiEVP and CFOSSale−1.18K$427.21−$505.4K−11.3%9.26K after
Jan 26, 2026 (view filing)Jan 26Same dayHuntsman CaroleChief Commercial OfficerSSale−910$493.78−$449.3K−9.1%9.12K after2 lots10b5-1
Jan 26, 2026 (view filing)Jan 26Same daySibold William JohnPresident and CEOSSale−1.58K$492.42−$776.5K−1.1%148.5K after
Jan 26, 2026 (view filing)Jan 26Same dayTaub RebeccaDirectorSSale−647$492.42−$318.6K−0.1%452.7K after
Jan 20, 2026 (view filing)Jan 20Same dayKelley Shannon TGeneral CounselSSale−692$497.36−$344.2K−7.5%8.48K after2 lots10b5-1
Jan 20, 2026 (view filing)Jan 20Same dayTaub RebeccaDirectorSSale−2.24K$490.77−$1.10M−0.5%453.4K after
Jan 13, 2026 (view filing)Jan 94 daysFriedman Paul ADirectorSSale−280$551.24−$154.3K−0.1%187.2K after10b5-1
Jan 13, 2026 (view filing)Jan 94 daysFriedman Paul ADirectorSSale−24.5K$522.39−$12.8M−11.6%187.2K after28 lots10b5-1
Jan 13, 2026 (view filing)Jan 94 daysTaub RebeccaDirectorSSale−240$550.33−$132.1K−0.1%455.6K after2 lots10b5-1
Jan 13, 2026 (view filing)Jan 94 daysTaub RebeccaDirectorSSale−18.4K$522.40−$9.62M−3.9%455.6K after28 lots10b5-1
Dec 12, 2025 (view filing)Dec 102 daysFriedman Paul ADirectorSSale−24.8K$552.18−$13.7M−11.7%187.2K after9 lots10b5-1
Dec 12, 2025 (view filing)Dec 102 daysTaub RebeccaDirectorSSale−18.6K$552.15−$10.3M−3.9%461.0K after9 lots10b5-1
Dec 4, 2025 (view filing)Dec 4Same daySibold William JohnPresident and CEOSSale−2.40K$575.34−$1.38M−1.6%150.1K after
Dec 3, 2025 (view filing)Dec 21 dayDier MardiEVP and CFOSSale−4.17K$578.34−$2.41M−28.6%10.4K after15 lots10b5-1
Nov 21, 2025 (view filing)Nov 21Same dayHuntsman CaroleChief Commercial OfficerSSale−1.96K$553.11−$1.08M−16.3%10.0K after11 lots10b5-1
Nov 14, 2025 (view filing)Nov 131 dayLevy Richard SDirectorSSale−8.50K$520.96−$4.43M−28.6%21.2K after14 lots10b5-1
Nov 7, 2025 (view filing)Nov 52 daysBate KennethDirectorSSale−16.6K$484.31−$8.03M−86.3%2.63K after11 lots
Sep 9, 2025 (view filing)Sep 9Same daySibold William JohnPresident and CEOSSale−7.28K$445.63−$3.24M−6.6%102.5K after
Aug 21, 2025 (view filing)Aug 21Same daySibold William JohnPresident and CEOSSale−7.62K$400.17−$3.05M−6.5%109.8K after2 lots10b5-1
Aug 20, 2025 (view filing)6:12 PM ETAug 18-202 daysBaker Julian and 5 othersDirectorPPurchase+97.1K$380.58+$36.9M+5.2%1.95M after26 lots
Aug 20, 2025 (view filing)6:09 PM ETAug 182 daysBaker Julian and 5 othersDirectorPPurchase+68.6K$364.04+$25.0M+3.8%1.86M after28 lots
Aug 18, 2025 (view filing)Aug 18Same dayKelley Shannon TGeneral CounselSSale−1.30K$367.81−$479.6K−12.4%9.17K after8 lots10b5-1
Aug 15, 2025 (view filing)Aug 15Same dayBate KennethDirectorSSale−10.0K$365.20−$3.65M−79.2%2.63K after6 lots
Aug 13, 2025 (view filing)Aug 11-122 daysTaub RebeccaDirectorSSale−46.5K$355.31−$16.5M−9.2%461.0K after12 lots10b5-1
Aug 13, 2025 (view filing)Aug 13Same dayFriedman Paul ADirectorSSale−129.2K$370.24−$47.8M−40.8%187.2K after17 lots10b5-1
Aug 13, 2025 (view filing)Aug 11-122 daysFriedman Paul ADirectorSSale−46.8K$355.31−$16.6M−20.0%187.2K after12 lots10b5-1
Jul 22, 2025 (view filing)Jul 184 daysTaub RebeccaDirectorSSale−1.00K$350.01−$350.0K−0.2%461.0K after10b5-1
Jul 22, 2025 (view filing)Jul 184 daysFriedman Paul ADirectorSSale−1.40K$350.03−$490.0K−0.7%187.2K after10b5-1
Jul 18, 2025 (view filing)Jul 16-172 daysFriedman Paul ADirectorSSale−28.9K$353.19−$10.2M−13.4%187.2K after9 lots10b5-1
Jul 18, 2025 (view filing)Jul 16-172 daysTaub RebeccaDirectorSSale−29.1K$353.19−$10.3M−5.9%461.0K after9 lots10b5-1
Mar 14, 2025 (view filing)Mar 12-132 daysCraves Fred BDirectorSSale−15.5K$328.54−$5.08M−4.2%350.1K after13 lots
Mar 12, 2025 (view filing)Mar 102 daysDier MardiSVP and CFOSSale−258$323.04−$83.3K−2.4%10.4K after10b5-1
Mar 7, 2025 (view filing)Mar 52 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−14.1K$341.33−$4.82M−79.1%3.73K after9 lots
Mar 5, 2025 (view filing)Mar 32 daysKelley Shannon TGeneral CounselSSale−415$335.00−$139.0K−5.4%7.29K after10b5-1
Mar 5, 2025 (view filing)Mar 32 daysDier MardiSVP and CFOSSale−1.96K$324.96−$637.3K−22.1%6.91K after2 lots10b5-1
Mar 5, 2025 (view filing)Mar 32 daysHuntsman CaroleChief Commercial OfficerSSale−1.83K$325.98−$597.8K−17.6%8.60K after9 lots10b5-1
Mar 4, 2025 (view filing)Feb 284 daysWaltermire Robert E.Senior VP, Chief Pharma Dev.SSale−1.23K$341.07−$418.5K−24.8%3.73K after2 lots
Feb 28, 2025 (view filing)Feb 271 dayDaly James MDirectorSSale−15.5K$347.45−$5.38M−89.0%1.91K after3 lots
Feb 28, 2025 (view filing)Feb 271 dayBate KennethDirectorSSale−20.0K$356.44−$7.13M−91.3%1.91K after9 lots